Literature DB >> 24588262

Fresh approaches to antidepressant drug discovery.

Christoph Anacker1.   

Abstract

INTRODUCTION: The success of antidepressant research has long been challenged by a limited mechanistic understanding of depression pathogenesis and antidepressant treatment response. Progress in this field has thereby consistently been hindered by a lack of novel conceptual approaches and sophisticated experimental techniques to dissect the highly intricate neurobiology of depression. Using fresh approaches to investigate the cellular and molecular mechanisms underlying depression will thus be vital for discovery of novel antidepressant targets. AREAS COVERED: This article provides an overview of some fundamental problems that depression research is currently facing and critically evaluates how these issues could be addressed by future research. It also discusses novel conceptual and technological advances in the field of neuroscience, particularly in regard to how they may help in providing unprecedented insight into the molecular mechanisms of depression pathogenesis. EXPERT OPINION: Although progress in antidepressant drug discovery has been limited over recent years, modern innovations in neuroscience, molecular biology, genetics and bioinformatics are just beginning to revolutionize depression research and to reveal novel and promising treatment targets. Integrating findings from a range of relevant experimental models and using the most advanced technology will be vital for the future success of antidepressant drug discovery.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24588262     DOI: 10.1517/17460441.2014.892071

Source DB:  PubMed          Journal:  Expert Opin Drug Discov        ISSN: 1746-0441            Impact factor:   6.098


  4 in total

1.  The Potential of KCNQ Potassium Channel Openers as Novel Antidepressants.

Authors:  Sara Costi; Ming-Hu Han; James W Murrough
Journal:  CNS Drugs       Date:  2022-03-08       Impact factor: 5.749

2.  Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial.

Authors:  Sara Costi; Laurel S Morris; Katherine A Kirkwood; Megan Hoch; Morgan Corniquel; Brittany Vo-Le; Tabish Iqbal; Nisha Chadha; Diego A Pizzagalli; Alexis Whitton; Laura Bevilacqua; Manish K Jha; Stefan Ursu; Alan C Swann; Katherine A Collins; Ramiro Salas; Emilia Bagiella; Michael K Parides; Emily R Stern; Dan V Iosifescu; Ming-Hu Han; Sanjay J Mathew; James W Murrough
Journal:  Am J Psychiatry       Date:  2021-03-03       Impact factor: 18.112

3.  Synthesis and evaluation of new 1,5-diaryl-3-[4-(methyl-sulfonyl)phenyl]-4,5-dihydro-1H-pyrazole derivatives as potential antidepressant agents.

Authors:  Ahmet Özdemir; Mehlika Dilek Altıntop; Zafer Asım Kaplancıklı; Özgür Devrim Can; Ümide Demir Özkay; Gülhan Turan-Zitouni
Journal:  Molecules       Date:  2015-02-04       Impact factor: 4.411

4.  Panax ginseng exerts antidepressant-like effects by suppressing neuroinflammatory response and upregulating nuclear factor erythroid 2 related factor 2 signaling in the amygdala.

Authors:  Jong Hee Choi; Min Jung Lee; Minhee Jang; Hak-Jae Kim; Sanghyun Lee; Sang Won Lee; Young Ock Kim; Ik-Hyun Cho
Journal:  J Ginseng Res       Date:  2017-04-29       Impact factor: 6.060

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.